CHRNA7 viability uncertain after Neuphoria’s Phase II Alzheimer’s miss

Notable updates from the clinic were light this week with a single sizeable stock drop from Neuphoria after terminating its Merck-partnered Phase II Alzheimer’s study for MK-1167, putting the future of the CHRNA7 modulator in question.

Neuphoria Therapeutics Inc. (NASDAQ:NEUP) and Merck & Co. Inc. (NYSE:MRK) quietly changed the status last Wednesday of MK-1167 in Alzheimer’s disease to “terminated for business reasons” on ClinicalTrials.gov without issuing a formal press release...